Work

Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial

Year: 2014

Type: article

Source: Blood

DOI: 10.1182/blood.v124.21.3181.3181

Authors: Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N Harrison, Fabrizio Pane, Pierre Zachee, Ruben Mesa, Mark M Jones, Shui He, Jingjin Li, Dany Habr, Srdan Verstovsek

Institutions: Hôpital Saint-Louis, Université Paris Diderot, University of Florence, Johannes Wesling Klinikum Minden, Semmelweis University, Unified Szent István and Szent László Hospital, Royal Brisbane and Women's Hospital, Ospedale di Circolo e Fondazione Macchi, Guy's and St Thomas' NHS Foundation Trust, University of Naples Federico II, Ziekenhuisnetwerk Antwerpen Stuivenberg, Mayo Clinic, Mayo Clinic in Arizona, Incyte (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2564167895

FWCI: 0.313

Cites:

Cited by: 2

Related to: 10